Safe AQ Easy Blood Glucose Monitoring System; Safe AQ Care Blood Glucose Monitoring System
Changsha Sinocare, Inc. · Decision date Oct 30, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 30 October 2026 for K260738, covering the Safe AQ Easy Blood Glucose Monitoring System and the Safe AQ Care Blood Glucose Monitoring System submitted by Changsha Sinocare, Inc. of Changsha, Hunan, China. The application was received on 6 March 2026 and falls under regulation number 862.1345, product code NBW, in the Clinical Chemistry specialty and review panel.
SESE denotes 510(k) clearance rather than premarket approval. The public record lists no summary statement, so the specific device components, any changed items relative to a predicate device, and the basis for the equivalence determination are not described in the available material. The page also records that the submission was not reviewed by a third party, was not a combination product, and had no authorized predetermined change control plan.
Details of the cleared configurations, performance data and labeling remain outside this record and would need the underlying FDA decision documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Oct 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260738
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Changsha Sinocare, Inc.
- Product code
- NBW
- Decision code
- SESE
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Test, Blood Glucose, Over The Counter.
- Applicant
- Changsha Sinocare, Inc.
- Product code
- NBW
- FDA device class
- 2
FDA decision timeline
K260738 received
Application receipt date recorded by FDA.
K260738 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NBW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| EPS Bio Technology Corp. | 510(k) clearance | Oct 23, 2026 | FDA | |
| Vivachek Biotech (Hangzhou) Co., Ltd. | 510(k) clearance | Oct 9, 2026 | FDA | |
| I-Sens, Inc. | 510(k) clearance | Oct 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Changsha Sinocare, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Changsha, Hunan
Sources and methodology
- Original FDA record: K260738
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

